Pacific Biosciences
PACB
PACB
234 hedge funds and large institutions have $1.83B invested in Pacific Biosciences in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 65 increasing their positions, 76 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
4% more funds holding
Funds holding: 225 → 234 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
14% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 76
Holders
234
Holding in Top 10
3
Calls
$24.6M
Puts
$14.5M
Top Buyers
| 1 | +$34.5M | |
| 2 | +$32.8M | |
| 3 | +$22.9M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.9M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$8.5M |
Top Sellers
| 1 | -$43M | |
| 2 | -$24.5M | |
| 3 | -$19.2M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.3M |
| 5 |
DM
Deerfield Management
New York
|
-$11.7M |